Company profile
Pacific Biosciences of California, Inc.
NASDAQ: PACB · Healthcare · Medical - Devices
#304 of 1,418 Healthcare companies by revenue47th-percentile growth
EA Score
55CFH 37DQ 79GM 54SS 73
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$160.0M
Rev growth YoY (TTM)
+5.0%
Net income (FY)
-$546.4M
Employees
485
as of 2026-08-11
Market cap
$357.2M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$160.0M$160.0M2025
Net income-$546.4M-$546.4M2025
Operating income-$553.9M-$553.9M2025
Total assets$784.1M$784.1M2025
Liabilities$778.7M$778.7M2025
Equity$5.3M$5.3M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product46%
Consumable28%
Instrument18%
Service And Other8%
By geography
Americas32%
UNITED STATES30%
EMEA19%
Asia Pacific19%
The read
What is Pacific Biosciences of California, Inc.’s revenue?
Pacific Biosciences of California, Inc. booked $160.0M in FY2025 revenue, growing 3.9% year over year — about the middle of the pack among Healthcare companies we track, at a -341.5% net margin.
Peers · Healthcare
REGENXBIO Inc.54DGinkgo Bioworks Holdings, Inc.44DMaze Therapeutics, Inc.49DMariMed Inc.66BLiquidia Corporation58CHeron Therapeutics, Inc.58CNeighbors
San Mateo →Key facts
CEOChristian O. Henry
SectorHealthcare
IndustryMedical - Devices
HeadquartersMenlo Park, CA
ExchangeNASDAQ: PACB
Employees485
IPO date2010-10-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.